EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Incremental Prognostic Value of Heart‐Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study

Xinqing Li iD, Anran Xin iD, Guo Ai iD, Chengyi Wang, Xuemei Zhao, Yan Huang, Xiaofeng Zhuang, Huihui Liu, Qiong Zhou, Jian Zhang, Yuhui Zhang iD

Clinical and Translational Science · 2026-04 · 19 (4)

DOI: 10.1111/cts.70559 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Translational Science, online erschienen am 17.04.2026. Verfasst von Xinqing Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of…. Hauptthemen laut MEDLINE: Fatty Acid Binding Protein 3, Cardiomyopathies, Immunoglobulin Light-chain Amyloidosis, Fatty Acid-Binding Proteins. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The utility of heart‐type fatty acid binding protein (H‐FABP) as a prognostic biomarker in light chain cardiac amyloidosis (AL‐CA) patients remains unestablished. Consecutive patients diagnosed with AL‐CA in the Heart Failure Center; Fuwai Hospital were enrolled. Baseline H‐FABP levels categorized patients as low (≤ 9.5 ng/mL) or high (> 9.5 ng/mL) group. Kaplan–Meier analysis and Cox proportional hazards models were performed. Model performance was assessed using Harrell's C concordance index (C‐index), integrated discrimination improvement (IDI) index, and net reclassification improvement (NRI) index. Eighty‐four patients were included (mean age 60.12 ± 11.25 years; 32.1% female), with 30 (35.7%) in the high H‐FABP group. Overall survival was significantly lower in the high H‐FABP group. In multivariable Cox models adjusted for age, eGFR and chemotherapy, H‐FABP > 9.5 ng/mL remained independently associated with an increased risk of all‐cause mortality when incorporating either the European modified Mayo 2004 stages [adjusted hazard ratio (HR): 2.79, 95% confidence interval (CI): 1.49–5.22; p = 0.001] or the revised Mayo 2012 stages (HR: 2.67, 95% CI: 1.48–4.83; p = 0.001). Adding H‐FABP levels significantly improved predictive performance across both baseline staging systems. For the European modified Mayo 2004 stage, the C‐index increased from 0.622 to 0.663, accompanied by positive IDI (0.053) and NRI (0.294). Similarly, for the revised Mayo 2012 stage, the C‐index increased from 0.611 to 0.660, with positive IDI (0.074) and NRI (0.308). Elevation of H‐FABP is associated with an increased risk of all‐cause mortality in patients with AL‐CA. It provides significant additive prognostic value to the established staging system for prognosis in AL‐CA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acid Binding Protein 3CardiomyopathiesImmunoglobulin Light-chain AmyloidosisFatty Acid-Binding ProteinsHumansFemalePrognosisBiomarkersProspective StudiesMiddle AgedMaleAgedKaplan-Meier Estimate

Stichwörter der Autor:innen

H‐FABPlight chain cardiac amyloidosisprognosis

Substanzen

Fatty Acid Binding Protein 3BiomarkersFABP3 protein, humanFatty Acid-Binding Proteins

Autor:innen und Institutionen

  • Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijin…

ORCID-Profile: Xinqing Li, Anran Xin, Guo Ai, Yuhui Zhang

Zitieren

APA

Li, X., Xin, A., Ai, G., Wang, C., Zhao, X., Huang, Y., Zhuang, X., Liu, H., Zhou, Q., Zhang, J., & Zhang, Y. (2026). Incremental Prognostic Value of Heart‐Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study. Clinical and Translational Science, 19(4). https://doi.org/10.1111/cts.70559

Vancouver

Li X, Xin A, Ai G, Wang C, Zhao X, Huang Y, et al. Incremental Prognostic Value of Heart‐Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study. Clinical and Translational Science. 2026;19(4). doi:10.1111/cts.70559

BibTeX
@article{Li2026,
  author = {Li, Xinqing and Xin, Anran and Ai, Guo and Wang, Chengyi and Zhao, Xuemei and Huang, Yan and Zhuang, Xiaofeng and Liu, Huihui and Zhou, Qiong and Zhang, Jian and Zhang, Yuhui},
  title = {Incremental Prognostic Value of Heart‐Type Fatty Acid Binding Protein in Patients With Light Chain Cardiac Amyloidosis: A Prospective Cohort Study},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {4},
  doi = {10.1111/cts.70559}
}
Kostenlos starten →